In a significant move to safeguard health rights, the Delhi High Court has mandated the Centre and Delhi government to submit comprehensive reports on the availability of Antihemophilic Factor (AHF) injections, crucial for treating hemophilia, a rare genetic blood disorder. Justice Sanjeev Narula issued the order on November 28, requiring the reports to detail stock levels and the supply chain system for hospitals under their jurisdiction by December 12.
The directive emerged from a plea filed by several individuals afflicted with hemophilia, highlighting the challenges they face due to frequent shortages of AHF injections in government hospitals. The petition underscored the high cost and critical need for these injections in managing the disorder, which can place lives in jeopardy when supplies falter.
“Given the severity of the disorder and the essential nature of the treatment, it is paramount that there are no interruptions in the supply of AHF injections,” Justice Narula noted in his order. The court also asked for updates on the existing supply chain mechanisms to ensure they are robust and responsive to patient needs.
The petitioners have urged for a proactive approach from the government bodies, calling for enhanced monitoring of supply chain management and the establishment of contingency plans to address any critical shortages of the medication effectively.
